Ibogaine: A Story of my life and years

Howard S. LotsofDora Weiner Foundation

Staten Island, NY

Ibogaine: Providers and FacilitatorsConference

A Tribute to Howard LotsofSayulita, Mexico

March 20 - 27, 2009

Ibogaine Found in the West African plant Tabernanthe iboga

Iboga alkaloids are concentrated in the bark of the root

Usable forms include scraped or ground root bark

Total Alkaloid extract

Purified Chemical

Ibogaine:Stages of effect

1. Visualization or waking dream-like experience

3 - 6 hours

2. Cognitive evaluation8 - 20 hours

3. Residual stimulation12 - 72 hours

Ibogaine:Side-effects

1. Nausea or vomiting

2. Ataxia

Ibogaine & Withdrawal - Early findings ca. 1995 -

http://ibogaine.org/ibonarco.htm

1. While ibogaine effects may be generalized, they are also specific to each individual.

2. Each person treated and each experience has unique characteristics that must be observed and responded to uniquely.

3. The administration of ibogaine requires, art, craft and practice as do all human endeavor.

Technology Transfer

Ibogaine Advantages

1. Ibogaine significantly reduces withdrawal

2. Interrupts drug craving

3. Interrupts drug self-administration

4. Returning patients to a preaddictive state

5. Antibacterial

6. Returns free choice

7. Eliminates stigma

Regulatory and Scientific Development

The first attempt at drug development of ibogaine was by the Dora Weiner Foundation in 1983.

In 1986, a for-profit corporation, NDA International, Inc. was established and subsequently raised 4 million towards the approval of ibogaine, initiating research and patent development.

1991, National Institute on Drug Abuse ibogaine research project.

1993, FDA approval for University of Miami clinical study.

Ibogaine Patents1. Rapid method for interrupting the narcotic

addiction syndrome, US 4,499,096 (1985)

2. Rapid method for interrupting the cocaine and amphetamine abuse syndrome US 4,587,243 (1986)

3. Rapid method for attenuating the alcohol dependency syndrome, US 4,957,523 (1989)

4. Rapid method for interrupting or attenuating the nicotine/tobacco dependency syndrome, US 5,026,697 (1991)

5. Rapid method for interrupting or attenuating poly-drug dependency syndromes, US 5, 124,994 (1992)

Lotsof periodhistorical development

First scientific publication of ibogaine antiaddictive effects

National Institute on Drug Abuse (NIDA) funds 85% of drug addiction research worldwide

NIDA Initially Rejects Ibogaine Research.

NIDA was petitioned to perform ibogaine research between 1984 - 1990, first by the Dora Weiner Foundation and from 1986 on by NDA International, Inc., a company established to make ibogaine available as an approved medication. In 1991, NIDA formed its Medications Development Division (MDD) and accepted a Product Profile Review (PPR) from NDA International that resulted in NIDA starting their ibogaine research program.

Additional research supports Dr. Dzoljic’s findings. Dr. Stanley D. Glick at Albany Medical College begins the publication of what will be dozens of research

papers

Ibogaine effects on Morphine self-administration

(Glick et al. 1991)

Ibogaine effects on Morphine withdrawal

(Glick et al. 1992)

Ibogaine effects on cocaine (Cappendijk & Dzoljic. 1993)

Ibogaine effects on alcohol

(Rezvani et al. 1995)

Ibogaine

1) User discovered

2) User developed

3) User supported

Ibogaine Activist Advocacy Organizations PlayRole in Ibogaine Development

• International Coalition for Addict Self-Help (ICASH) 1989

• Dutch Addict Self-Help (DASH) 1990

• Cures-Not Wars (ibogaine and other issues) 1994

• Ibogaine Underground 2004

ICASH logoUsed to attract attention of government

officials and media

Nico Adriaans was one of the founders of both the Rotterdam Junkies Union and Dutch Addict Self-Help (DASH). DASH was an ibogaine self-help organization that petitioned the Dutch government and organized drug users to demand ibogaine availability. DASH provided ibogaine at no cost to heroin users.

ICASH Organizing in the US

Cures-Not-Wars placed pressure on NIDA to support Ibogaine

research through protests

Mindvox internet ibogaine list(user advocacy continues)

“We all got to help each other best we can. No one else gives a shit ‘bout us hippy freak junkies? ”

anon.To join send an email to

ibogaine-subscribe@mindvox.com

“FM- … We feel that continuing the focus offshore, outside the US, has not served a majority of people inside the US. Like many other grassroots movements, which facilitated change, treatments, sessions, need to be done where they belong, in all major US cities, as cost effectively as possible. “

http://www.drugwar.com/ibonyc.shtm

Ibogaine underground appears 2004

Ibogaine:Question #1

asked by users

Will it get rid of withdrawal?

Opioid withdrawal in

human subjects Early study shows significant efficacy in 25 out of 33 cases.- Resolution of opioid withdrawal without signs of drug seeking behavior -

NIDA has focused on already existing drugs which are then developed for addiction as a new indication, and not the development of fundamentally new pharmacological strategies such as ibogaine.

NIDA director signs agreement to develop buprenorphine 1994

NIDA says “NO” to funding clinical development of ibogaine 1995

Ibogaine Prohibition“a growing problem”

1. United States 1967

2. Belgium 1987

3. Switzerland 1989

4. Sweden 1999

5. Denmark 2003

6. France 2007

Why ibogaine should be available

1. Ibogaine significantly reduces withdrawal

2. Interrupts drug craving

3. Returns users to a preaddictive state

4. Eliminates stigma

5. Offers freedom of choice

Ibogaine advocates are seeking a new generation of activists to allow technology transfer, training and treatment.

It is your right to use drugs and your right to stop.

We would like to share the technology that allows you to stop or limit use on your terms.

It’s in your hands now! Patient rights - User rightsFreedom - Not oppression